USC Price’s Genevieve Kanter explains the privacy risks that clinicians are taking when they use AI chatbots.
Researchers looked at a cancer therapy drug and found biosimilars bring competition to the market, with prices declining by more than half for some versions.
An international leader in Alzheimer’s disease research for over 30 years, Aisen is recognized with the highest academic honor at the Keck School of Medicine of USC.
Researchers at USC’s Information Sciences Institute used machine learning and deep statistical analysis to look for answers about vaccine hesitancy.
A USC Schaeffer Center study — the first to examine biosimilar drivers — finds commercial insurers limit use in almost 20% of cases. Restrictions are greatest for pediatric patients.
Surgeons with Keck Medicine of USC launch a clinical trial to enroll first-ever bladder transplant patient after multiple successful research procedures.
USC’s Vsevolod “Seva” Katritch discusses how structure-based virtual screening and AI could disrupt the time-consuming, expensive process of drug discovery.
Researchers propose three strategies for mitigating negative impacts of the Inflation Reduction Act to ensure greater patient access, increased innovation and lower costs.
USC’s Dana Goldman and Karen Van Nuys explain why the drug company is dramatically cutting the cost of some of its insulin products and sum up how it may improve access to this essential medical treatment.
Scientists at USC Dornsife and the USC Michelson Center for Convergent Bioscience are hoping to spark drug research across the university by hosting a series of workshops starting Friday.